Abiomed downgraded by Deutsche Bank with a new price target
$ABMD
Medical/Dental Instruments
Health Care
Deutsche Bank downgraded Abiomed from Buy to Hold and set a new price target of $388.00 from $355.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/2/2022 | $235.00 → $380.00 | Underweight → Equal-Weight | Morgan Stanley |
| 11/2/2022 | $355.00 → $388.00 | Buy → Hold | Deutsche Bank |
| 10/13/2022 | $300.00 | Buy | Mizuho |
| 4/6/2022 | $330.00 | Peer Perform | Wolfe Research |
| 2/4/2022 | $292.00 → $275.00 | Underweight | Morgan Stanley |
| 2/4/2022 | $345.00 → $325.00 | Market Perform | SVB Leerink |
| 1/7/2022 | $269.00 → $292.00 | Underweight | Morgan Stanley |
| 8/6/2021 | $335.00 → $375.00 | Market Perform | SVB Leerink |